Edition:
United States

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

257.40SEK
21 Sep 2018
Change (% chg)

-12.10kr (-4.49%)
Prev Close
269.50kr
Open
270.00kr
Day's High
270.30kr
Day's Low
257.40kr
Volume
2,731,675
Avg. Vol
878,704
52-wk High
299.60kr
52-wk Low
107.40kr

Select another date:

Fri, Jul 20 2018

CORRECTED-Sweden's Sobi buys rights for emapalumab drug, strengthening inflammation business

STOCKHOLM, July 20 Drugmaker Swedish Orphan Biovitrum (Sobi) said on Friday it had reached an exclusive licensing deal with Swiss firm Novimmune SA for the perpetual global rights to emapalumab, a late-stage orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis.

Select another date: